POINT Biopharma Global Inc.

POINT Biopharma Global Inc. (Nasdaq: PNT) is a radiopharmaceutical company focused on targeted cancer therapies, including radioligand treatments for oncology indications. The company became publicly traded in 2021 through a business combination with GX Acquisition Corp. II, a healthcare-focused blank-check company that completed its IPO in 2020. The S-1 registration statement filed July 30, 2021 covers post-merger share registration for the combined entity. POINT Biopharma operated in the biotechnology and radiopharmaceuticals sector before being acquired by Eli Lilly and Company in 2023, concluding its tenure as an independent public company. Sign up at SpacDesk for complete filings data, deal timelines, and analytics across the SPAC universe.